In this study, we established a novel immunologic gene prognostic index (IGPI) to predict metastasis and provided new insights into tumor immune microenvironment (TIME) for PCa patients receiving radical radiotherapy. GBP2 and IGF1 were independent factors associated with metastasis-free survival. IGPI score was calculated based on GBP2 and IGF1 and this score was an independent risk factor for PCa patients undergoing radical radiotherapy. Patients with higher IGPI score were at higher risk of metastasis and biochemical recurrence, which were externally validated in the TCGA database and other GEO datasets. IGPI score had demonstrated moderate diagnostic ability of radiation resistance (AUC: 0.889). This score increased with the augment of Gleason score and T stage, as well as biochemical recurrence. Using EPIC, ESTIMATE and immunophenoscore (IPS) algorithms, cancer associated fibroblasts (CAFs), macrophages, stromal score, and estimate score were significantly higher in patients with metastasis group compared to their counterpart. Besides, for CAFs, macrophages, stromal score, and estimate score, patients with higher scores were at higher risk of metastasis, and the HRs were 3.65, 4.01, 4.27, and 3.78, respectively. IGPI score was highly positively associated with stromal score (coefficient: 0.39), immune score (coefficient: 0.43), estimate score (coefficient: 0.45), CAFs (coefficient: 0.42) and macrophages (coefficient: 0.42), while showing the opposite relationship with tumor purity (coefficient: − 0.45). In conclusion, we found that IGPI based on GBP2 and IGF1 might serve as a biomarker predicting metastasis for PCa patients. Besides, the current data further highlight the importance of CAFs in the metastatic process of PCa.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Dear editor,
Among genitourinary cancers, prostate cancer (PCa) has seen the greatest increase in global incident cases over the last 30 years [1]. There has been growing recognition of the vital links between PCa and immunotherapy, including checkpoint inhibitors, cytokines, and therapeutic cancer vaccines [2]. We previously developed an immune-related gene signature to predict progression and immune infiltration for PCa patients undergoing radical prostatectomy [3]. However, radical radiotherapy, as another preferred treatment for intermediate or high-risk localized patients, is rarely studied. About 30% of patients might undergo recurrence as a result of metastasis disease, radioresistant clones and unsatisfactory treatments [4]. In this study, we remedied these problems through establishing a novel immunologic gene prognostic index (IGPI) to predict metastasis and provides new insights into tumor immune microenvironment (TIME) for PCa patients receiving radical radiotherapy. We provided a full-text article in the Additional file 1 for the detailed methods and materials used in this study.
Anzeige
182 differentially expressed genes (Fig. 1A), 4519 tumor-related genes through weighted gene co-expression network analysis (Fig. 1B) and 2660 immune-related genes were used to identify 21 candidate genes (Fig. 1C). Univariate and multivariate COX regression analyses indicated that GBP2 and IGF1 were independent factors associated with metastasis-free survival (Fig. 1D). IGPI score was calculated based on GBP2 and IGF1 and this score was an independent risk factor for PCa patients undergoing radical radiotherapy (Fig. 1E). IGPI score presented certain diagnostic accuracy for metastasis (Fig. 1F). We divided PCa patients according to the median value of IGPI score and patients with higher IGPI score were at higher risk of metastasis (HR: 9.57; 95%CI: 3.23–28.33; Fig. 1G) and biochemical recurrence (BCR) (HR: 3.83; 95%CI: 2.22–6.61; Fig. 1H). In the GSE21034 [5], IGPI score also presented certain value of diagnostic accuracy (AUC: 0.802; 95%CI: 0.702–0.902; Fig. 1I). In addition, patients with higher IGPI score had higher risk of metastasis (HR: 3.85; 95%CI: 2.20–6.74; Fig. 1J) in the GSE134051 [6] and progression (HR: 1.62; 95%CI: 1.08–2.44; Fig. 1K) in the TCGA database. IGPI score had demonstrated moderate diagnostic ability of radiation resistance (AUC: 0.889) in the GSE53902 [7]. This score increased with the augment of Gleason score (Fig. 1M) and T stage (Fig. 1N), as well as BCR (Fig. 1O).
×
Gene set enrichment analysis indicated that high risk group was positively associated with apoptosis, circadian rhythm, cell cycle, T cell receptor signaling pathway, chemokine signaling pathway, mismatch repair, homologous recombination, ECM receptor interaction, and so on, while it was negatively related to arachidonic acid metabolism, fatty acid metabolism, tyrosine metabolism, glutathione metabolism, and drug metabolism cytochrome P450 (Fig. 2A). Furthermore, we established the competing endogenous RNA network and identified the function axis of PART1/has-miR-6885-3p/IGF1 and GBP2 (Fig. 2B). Using EPIC, ESTIMATE and immunophenoscore (IPS) algorithms [8], cancer associated fibroblasts (CAFs), macrophages, stromal score, and estimate score were significantly higher in patients with metastasis group compared to their counterpart (Fig. 2C). Besides, for CAFs, macrophages, stromal score, and estimate score, patients with higher scores were at higher risk of metastasis, and the HRs were 3.65 (1.56–8.54), 4.01 (1.63–9.86), 4.27 (1.84–9.90), and 3.78 (1.58–9.01), respectively (Fig. 2C). However, tumor purity was significantly lower in metastasis group, and patients with higher score were less prone to metastasis compared to those with lower score (HR: 0.26; 95%CI: 0.11–0.63; Fig. 2C). IGPI score was highly positively associated with stromal score (coefficient: 0.39), immune score (coefficient: 0.43), estimate score (coefficient: 0.45), CAFs (coefficient: 0.42) and macrophages (coefficient: 0.42), while showing the opposite relationship with tumor purity (coefficient: − 0.45) (Fig. 2D).
×
Experimental evidence has implicated GBP2 and IGF1 in the metastasis of other tumors, such as breast cancer [9]. We found that immune-related pathways and ECM receptor interaction might participate in the metastasis of PCa. CAFs, as the most important stromal cells, mediate ECM deposition and remodeling in the reactive stroma and increase tissue stiffness and induce mechanical stress [10]. Prostatic CAFs could induce tumorigenesis in normal human prostatic epithelial cell in vitro via the secretion of CXCL12, and this mechanism was found to be dependent on the presence of TGF-β in vivo in a mouse model, which was consistent with our findings [11, 12].
Conclusion
We found that IGPI based on GBP2 and IGF1 might serve as a biomarker predicting metastasis for PCa patients.
Anzeige
Acknowledgements
The results showed here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.
Declarations
Ethics approval and consent to participate
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Consent for publication
Not applicable.
Competing interests
The authors have no conflicts of interest to declare.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.